Sol-Gel to Present at Upcoming Healthcare Investor Conferences in September

Rhea-AI Summary

Sol-Gel Technologies (NASDAQ: SLGL), a clinical-stage dermatology company, announced participation in upcoming virtual investor conferences. CEO Dr. Alon Seri-Levy will provide a company overview, while CFO Gilad Mamlok will represent Sol-Gel at the H.C. Wainwright Healthcare Conference on September 15, 2020, at 10:00 AM ET. Additionally, a fireside chat featuring Dr. Seri-Levy, Mr. Mamlok, and John Vieira is scheduled for the Cantor Fitzgerald Virtual Global Healthcare Conference on September 17, 2020, at 8:40 AM ET. Webcasts will be available on the company's website.

NESS ZIONA, Israel, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies (NASDAQ: SLGL), (“Sol-Gel”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the company will present at the following upcoming virtual investor conferences.

Dr. Alon Seri-Levy, Sol-Gel’s Chief Executive Officer, will provide an overview of the Company and give a business update.  A live webcast of the presentation will be available under the “Events and Presentations” in the investors section of the Company’s website at www.sol-gel.com. An archived webcast recording of the event will be available on the website for approximately 30 days.

H.C. Wainwright Healthcare Conference
Speaker:		Gilad Mamlok, Chief Financial Officer
Date:		September 15, 2020
Time:		10:00 AM ET
Cantor Fitzgerald Virtual Global Healthcare Conference – Fireside Chat
Speakers:		Dr. Alon Seri-Levy, Chief Executive Officer
		Gilad Mamlok, Chief Financial Officer
		John Vieira, U.S. Head of Commercialization
Date:		September 17, 2020
Time:		8:40 AM ET

About Sol-Gel Technologies
Sol-Gel is a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Sol-Gel leverages its proprietary microencapsulation technology platform for Twyneo, for the treatment of acne vulgaris, and Epsolay, for the treatment of papulopustular rosacea. The Company’s pipeline also includes SGT-210, an early-stage topical epidermal growth factor receptor inhibitor, erlotinib, for the treatment of punctate palmoplantar keratoderma, and preclinical assets tapinarof and roflumilast. For additional information, please visit www.sol-gel.com.

For further information, please contact:
Sol-Gel Contact:
Gilad Mamlok
Chief Financial Officer
+972-8-9313433

Investor Contact:
Lee Stern
Solebury Trout
+1-917-312-5998
lstern@soleburytrout.com

Source: Sol-Gel Technologies Ltd.

FAQ

What is the date for Sol-Gel's presentation at the H.C. Wainwright Healthcare Conference?

Sol-Gel will present at the H.C. Wainwright Healthcare Conference on September 15, 2020.

Who will speak at the Cantor Fitzgerald Virtual Global Healthcare Conference for Sol-Gel?

Dr. Alon Seri-Levy, Gilad Mamlok, and John Vieira will speak at the Cantor Fitzgerald Virtual Global Healthcare Conference.

What time is Sol-Gel's presentation at the H.C. Wainwright Healthcare Conference?

Sol-Gel's presentation at the H.C. Wainwright Healthcare Conference is scheduled for 10:00 AM ET.

When is the fireside chat featuring Sol-Gel executives?

The fireside chat featuring Sol-Gel executives is on September 17, 2020, at 8:40 AM ET.

Where can I find the archived webcasts of Sol-Gel's presentations?

Archived webcasts of Sol-Gel's presentations will be available on their website for approximately 30 days.